• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

June 17, 2015

View Archived Issues

Death cab for acuity? AVA-101 safety outcome solid in AMD phase IIa; Avalanche takes blow

Avalanche Biotechnologies Inc. touched off a Wall Street landslide by disclosing phase IIa results with gene therapy AVA-101 for wet age-related macular degeneration (AMD) that showed the trial's 12-month primary endpoint was met, based on ophthalmic and systemic safety. Read More

Vtv plots market debut to back Alzheimer's, diabetes drug trials

Vtv Therapeutics Inc., a new company formed by combining Transtech Pharma LLC and its affiliate High Point Pharmaceuticals LLC, has filed to raise up to $172.5 million in an IPO intended to help complete the company's formation and fund new trials of its lead programs, including a phase III study of its lead Alzheimer's disease (AD) drug candidate, azeliragon, and phase II trials of its type 2 diabetes drug candidates. Read More

Passion, achievement, need in 30 seconds: The art of the pitch

PHILADELPHIA – Capturing the attention of potential investors in 30 seconds or less poses a challenge for even the most sophisticated wordsmiths when attempting to describe complicated technologies and commercial potential. Read More

'Valley of death' bridged? Biopharma, academia look to 'real-world' solutions

PHILADELPHIA – For decades, young biotechs have circled the so-called "Valley of Death," trying not to fall into the funding chasm that can occur during the period between discovery and clinical proof of concept – the critical milestone when most venture capital (VC) firms are willing to get on board. Read More

Building a better antibody: Cytomx closes $70M series D for Probody pipeline

PHILADELPHIA – Anything an antibody can do, only better: That's the big idea behind Cytomx Inc.'s Probody platform, which, despite its early stage, has landed a couple of potentially lucrative big pharma deals. Read More

Luqa gets $15M boost for cross-border licensing operation in China

SHANGHAI – Luqa Pharmaceuticals' $15 million series A financing will boost efforts to acquire, develop and commercialize products for Chinese patients in the aesthetics and quality-of-life markets. Products include pharmaceuticals and devices for both the reconstructive and elective plastic surgery market. Read More

End 'p' value devotion, randomized control phase III trial designs

LONDON – It is time to end the devotion to 'p' values and the randomized control phase III study, and to give greater weight to novel trial designs that draw on real world observational data and take an inductive approach to probability. Read More

Experts call for industry-wide collaboration in orphan drug development

WASHINGTON – Stakeholders from the health care, patient, academic and clinical industries gathered at the Develop Innovate and Advance (DIA) 2015 annual meeting here to discuss, among other things, ways to improve orphan drug development to ensure patients with rare diseases receive timely, consistent, and effective treatment for their conditions. Read More

Regulatory front

The FDA sent two warning letters to online pharmacies demanding that they stop marketing unapproved drugs in the U.S. and selling prescription drugs without a valid prescription and outside approved risk evaluation and mitigation strategies (REMS). Read More

Stock movers

Read More

Financings

Kezar Life Sciences, of South San Francisco, completed a series A financing totaling $23 million. Morningside Venture, Cormorant Asset Management, EcoR1 Capital, 9W Capital Management, Omega Funds, Aju IB Investment, and private investors participated in the round. Read More

Other news to note

strong>Aerie Pharmaceuticals Inc., of Irvine, Calif., said the FDA has agreed in written and verbal communications that it may change the primary endpoint range of its second phase III registration trial of Rhopressa, named Rocket 2, to include patients with baseline intraocular pressures (IOPs) ranging from above 20 mmHg to below 25 mmHg. Read More

In the clinic

strong>Heron Therapeutics Inc., of Redwood City, Calif., has initiated a phase II trial of HTX-011, the company's lead candidate for the prevention of postoperative pain. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe